Pcr Testing for Covid has been purposefully over amplified to exaggerate cases

NOW ITS CYCLES ARE BEING BROUGHT TO LOWER LEVELS, AS VACCINES ARE ROLLED OUT.

Has this been whole situation been turned into an industry model? - globalised, as a social impact disease management business plan?

from what i can gather, It is impossible to vaccinate the world.

This is an economic continuum

a free-dynamo of fear and control

A FORCE MULTIPLIER FOR A NEW GLOBAL PHARMACEUTICALS INDUSTRY

BRUSSELS, April 21 (Reuters) - The European Union is paying 15.5 euros ($18.6) per dose of the Pfizer-BioNTech COVID-19 vaccine, according to the first contract it signed with the two companies which was leaked on Wednesday to Spanish newspaper La Vanguardia.

The price confirms what Reuters has reported in past months. Many media reported instead a lower number based on a document with partial prices briefly published on Twitter by a Belgian politician, who later deleted the tweet. .

The Belgian document, which included prices also for other jabs booked by the EU, fuelled the theory that the EU was facing delays in its vaccine supplies because it had paid too little. That was despite the AstraZeneca contract leaked in February that showed the price for that shot was higher than what was reported in the Belgian document.

Under the leaked contract with Pfizer, the EU agreed to pay on average 15.5 euros for the first 200 million doses. It also agreed to pay the same price for another 100 million optional doses which it ordered within a deadline set in the contract. Beyond that deadline it would have paid 17.5 euros per dose.

The EU in January signed a second contract for another 300 million doses with Pfizer-BioNTech that EU officials said kept the same price as the first contract.

The leaked contract also shows the EU gave Pfizer and BioNTech an upfront payment of 700 million euros in December to secure the first 200 million doses.

The bloc is now negotiating a third contract for a total of 1.8 billion doses with the two companies for 19.5 euros per dose, which would have stricter delivery conditions and the option for the EU to order enhanced vaccines against virus variants. ($1 = 0.8328 euros)

Yahoo news

May 4, 2021

Last year, racing to develop a vaccine in record time, Pfizer made a big decision: Unlike several rival manufacturers, which vowed to forgo profits on their shots during the Covid-19 pandemic, Pfizer planned to profit on its vaccine.

On Tuesday, the company announced just how much money the shot is generating.

The vaccine brought in $3.5 billion in revenue in the first three months of this year, nearly a quarter of its total revenue, Pfizer reported. The vaccine was, far and away, Pfizer's biggest source of revenue.

The company did not disclose the profits it derived from the vaccine, but it reiterated its previous prediction that its profit margins on the vaccine would be in the high 20 percent range. That would translate into roughly $900 million in pretax vaccine profits in the first quarter.

Pfizer has been widely credited with developing an unproven technology that has saved an untold number of lives. source NY Times

The first “tweaked” vaccine against the worrying coronavirus variants that emerged in South Africa and Brazil has successfully neutralised them in laboratory trials, the US company Moderna has said.

The results of the small trial suggest that boosters against the variants will be feasible and could be rolled out this year to counter the threat from variants that have appeared around the world and are feared in some cases to be more transmissible or partially vaccine-resistant.

Leading companies have been racing to produce adapted versions of their Covid vaccines. Pfizer/BioNTech, which has a similar mRNA vaccine to Moderna’s, and Oxford/AstraZeneca are also in the process of developing tweaked vaccines against the South African variant, B1351, and the Brazilian variant, P1, which appear to be the major threat to current immunisation programmes.

Moderna became the first to announce results on Wednesday night. They appear to be very positive, although only basic information from an initial analysis of results is available so far.

The US company has tested both a booster shot of its standard Covid vaccine and also a tweaked version of the vaccine in people who have previously had the full double dose. Twenty adults were recruited for each arm of the trial, or 40 in total.

Two weeks after the new jab, Moderna says both the booster shot and the tweaked vaccine increased the antibodies in the blood that can neutralise the two variants of concern.

But the tweaked vaccine – called mRNA-1273.351 and designed specifically to combat the South African and Brazilian variants, which have similar mutations to the spike protein – produced higher levels of neutralising antibodies than the standard booster shot, mRNA-1273.

Moderna says it is also running a trial in which people are given a mixture of the booster and the vaccine specifically designed against the variant. It has submitted the early results as a paper to a pre-print server, it said in a statement. Once the combined trial is complete, it will produce a paper that will be published with peer review.

“As we seek to defeat the ongoing pandemic, we remain committed to being proactive as the virus evolves. We are encouraged by these new data, which reinforce our confidence that our booster strategy should be protective against these newly detected variants,” said Stéphane Bancel, CEO of Moderna.

“Our mRNA platform allows for rapid design of vaccine candidates that incorporate key virus mutations, potentially allowing for faster development of future alternative variant-matched vaccines should they be needed … We will continue to make as many updates to our Covid-19 vaccine as necessary to control the pandemic.”

The vaccines have not been trialled in the field; these are blood samples analysed in the lab. But the regulatory authorities have said they would not need to go through the rigorous large-scale trials that were necessary for the original vaccines to obtain emergency approval.

The company said there were few side-effects from the vaccines and those that were reported were mild. Apart from pain at the injection site, the most common reported side-effects were fatigue, headache, muscle pain and joint pain.

yahoo

Your COVID vaccine booster might be a patch or a pill.
Or it might come with your flu shot.

May 3, 2021 - While the Biden administration has been racing to maximize the number of Americans vaccinated against COVID-19, government researchers have also been working on what form the next generation of vaccines will take.

They may be combined with the seasonal flu vaccine, or could come in the form of pills or patches instead of shots. Scientists also envision vaccines that might shield against viruses beyond SARS-CoV-2 (the virus that causes COVID-19) that could avert future pandemics.

And they're evaluating whether those who are fully vaccinated might need booster shots later this year.

Additional shots could be virtually identical to the first doses, given as a safeguard against the possibility of waning immunity or tweaked to defend against mutant strains that are raising concerns.

CBS News